Bill Would Prohibit Federal Comp Coverage for Cannabis

Why It Matters

It prevents federal employees from receiving cannabis‑based benefits even if the drug gains broader medical recognition, signaling a cautious federal stance that could influence state‑level reforms and employer policies.

Key Takeaways

• Appropriations bill bans cannabis in federal workers‑comp programs
• Prohibition applies even if marijuana moves to Schedule III
• December executive order sought Schedule III status for cannabis
• 2nd Circuit ruling upheld Schedule I barrier for compensation
• Federal policy may lag behind private‑sector cannabis adoption

Pulse Analysis

The latest labor appropriations bill underscores a growing tension between evolving cannabis policy and entrenched federal benefits structures. While the December executive order signaled a willingness to reclassify marijuana from Schedule I to Schedule III—recognizing legitimate medical uses—the appropriations language draws a hard line for federal workers’ compensation. By explicitly forbidding the Department of Labor from reimbursing or recognizing cannabis as a compensable treatment, Congress ensures that any scheduling change will not automatically translate into benefits for injured federal employees.

For federal workers, the restriction means that even if a physician prescribes a cannabis‑derived medication for a work‑related injury, the cost cannot be recovered through the Federal Employees' Compensation Act. This creates a disparity between federal and private‑sector employees, many of whom now enjoy broader access to cannabis‑based therapies under state laws or employer wellness programs. The decision also reflects judicial precedent; the 2nd Circuit’s March ruling cited the current Schedule I status to block claims that marijuana qualifies as a reasonable medical expense under the Longshore Harbor and Workers Compensation Act.

Looking ahead, the measure may set a de‑facto standard for other federal benefit programs, potentially slowing the integration of cannabis into broader health‑care coverage. Companies that employ large federal contractor workforces could feel pressure to align their own policies with the federal stance, while states continue to expand medical and recreational access. Stakeholders will watch how the Attorney General’s scheduling review unfolds and whether future appropriations or legislation will revisit the ban, especially as public opinion and market demand for cannabis‑based treatments keep rising.